Tags

Type your tag names separated by a space and hit enter

Pharmacotherapy of first episode psychosis in Estonia: comparison with national and international treatment guidelines.
J Clin Pharm Ther. 2008 Apr; 33(2):165-73.JC

Abstract

BACKGROUND AND OBJECTIVES

The pharmacotherapy of psychosis often differs between countries and with respect to treatment guidelines. Little is known about the treatment of first episode psychosis in countries of the former Soviet Union. The objective of the study was to analyse and describe the pharmacotherapy of first episode psychosis in Estonia.

METHODS

Case notes for consecutive patients with schizophrenia, schizotypal or delusional disorders admitted to the psychiatry clinics of the North Estonia Regional Hospital (NERH) and Tartu University Hospital (TUH) between September 2005 and September 2006 were retrospectively reviewed by a trained researcher. Treatment regimens were assessed according to prescribed doses, the incidence of antipsychotic polypharmacy and prescribing of conventional vs. atypical agents.

RESULTS

There were 234 patients admitted to the NERH and TUH, 142 of which were included in the final analyses (mean age 30.3 years for males, 40.4 years for females). Patients were most frequently treated with risperidone (n = 94), olanzapine (n = 43), chlorpromazine (n = 31), haloperidol (n = 21) and quetiapine (n = 24). Fourteen patients received concurrent treatment with two or more antipsychotics for three or more treatment days. Nine patients received antipsychotics in doses exceeding the maximum recommended doses in the British National Formulary.

CONCLUSIONS

The pharmacotherapy of first episode psychosis in Estonia was largely consistent with Estonian and international guidelines, however, the use of conventional antipsychotics and antipsychotic polypharmacy remained common. Estonian treatment guidelines may need to be revised to reflect the best available research evidence.

Authors+Show Affiliations

Pharmacy Department, Tartu University Hospital, Tartu, Estonia. jana.lass@kliinikum.eeNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article

Language

eng

PubMed ID

18315782

Citation

Lass, J, et al. "Pharmacotherapy of First Episode Psychosis in Estonia: Comparison With National and International Treatment Guidelines." Journal of Clinical Pharmacy and Therapeutics, vol. 33, no. 2, 2008, pp. 165-73.
Lass J, Männik A, Bell JS. Pharmacotherapy of first episode psychosis in Estonia: comparison with national and international treatment guidelines. J Clin Pharm Ther. 2008;33(2):165-73.
Lass, J., Männik, A., & Bell, J. S. (2008). Pharmacotherapy of first episode psychosis in Estonia: comparison with national and international treatment guidelines. Journal of Clinical Pharmacy and Therapeutics, 33(2), 165-73. https://doi.org/10.1111/j.1365-2710.2008.00900.x
Lass J, Männik A, Bell JS. Pharmacotherapy of First Episode Psychosis in Estonia: Comparison With National and International Treatment Guidelines. J Clin Pharm Ther. 2008;33(2):165-73. PubMed PMID: 18315782.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Pharmacotherapy of first episode psychosis in Estonia: comparison with national and international treatment guidelines. AU - Lass,J, AU - Männik,A, AU - Bell,J S, PY - 2008/3/5/pubmed PY - 2008/4/9/medline PY - 2008/3/5/entrez SP - 165 EP - 73 JF - Journal of clinical pharmacy and therapeutics JO - J Clin Pharm Ther VL - 33 IS - 2 N2 - BACKGROUND AND OBJECTIVES: The pharmacotherapy of psychosis often differs between countries and with respect to treatment guidelines. Little is known about the treatment of first episode psychosis in countries of the former Soviet Union. The objective of the study was to analyse and describe the pharmacotherapy of first episode psychosis in Estonia. METHODS: Case notes for consecutive patients with schizophrenia, schizotypal or delusional disorders admitted to the psychiatry clinics of the North Estonia Regional Hospital (NERH) and Tartu University Hospital (TUH) between September 2005 and September 2006 were retrospectively reviewed by a trained researcher. Treatment regimens were assessed according to prescribed doses, the incidence of antipsychotic polypharmacy and prescribing of conventional vs. atypical agents. RESULTS: There were 234 patients admitted to the NERH and TUH, 142 of which were included in the final analyses (mean age 30.3 years for males, 40.4 years for females). Patients were most frequently treated with risperidone (n = 94), olanzapine (n = 43), chlorpromazine (n = 31), haloperidol (n = 21) and quetiapine (n = 24). Fourteen patients received concurrent treatment with two or more antipsychotics for three or more treatment days. Nine patients received antipsychotics in doses exceeding the maximum recommended doses in the British National Formulary. CONCLUSIONS: The pharmacotherapy of first episode psychosis in Estonia was largely consistent with Estonian and international guidelines, however, the use of conventional antipsychotics and antipsychotic polypharmacy remained common. Estonian treatment guidelines may need to be revised to reflect the best available research evidence. SN - 1365-2710 UR - https://www.unboundmedicine.com/medline/citation/18315782/Pharmacotherapy_of_first_episode_psychosis_in_Estonia:_comparison_with_national_and_international_treatment_guidelines_ L2 - https://doi.org/10.1111/j.1365-2710.2008.00900.x DB - PRIME DP - Unbound Medicine ER -